2020
A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Wu J, Atkinson E, Leichman L, Patel H, Iqbal S, Du K, Bizekis C, Goldberg J, Thomas C, Cohen D, Becker D, Siolas D, Beri N, Oberstein P, Ku G. A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2020, 38: 372-372. DOI: 10.1200/jco.2020.38.4_suppl.372.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaClinical CRRadiation therapyPhase I/II studyCarboplatin/paclitaxelEfficacy of nivolumabGrade 2 esophagitisGrade 3/4 AEsGrade 5 toxicityOverall survival benefitPhase II portionSquamous cell carcinomaConcurrent chemoRTManageable toxicityLast dosePrimary endpointII studyUnacceptable toxicityElevated ASTSurvival benefitCell carcinomaChemoRTGrade 3Nivolumab
2018
A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Giuroiu I, Ku G, Leichman L, Du K, Oh P, Levinson B, Iqbal S, Thomas C, Wu J. A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2018, 36: tps199-tps199. DOI: 10.1200/jco.2018.36.4_suppl.tps199.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaPathologic complete responseOverall survivalClinical CRRadiation therapyMedian progression-free survivalPhase IEfficacy of nivolumabCarboplatin/paclitaxelOverall survival benefitProgression-free survivalKaplan-Meier curvesSquamous cell carcinomaMulti-center studyLast dosePrimary endpointUnacceptable toxicitySurvival benefitComplete responseMeier curvesAbscopal effectCell carcinomaExtensive tumorsEsophageal cancer
2016
Food as medicine: A randomized controlled trial (RCT) of home delivered, medically tailored meals (HDMTM) on quality of life (QoL) in metastatic lung and non-colorectal GI cancer patients.
Ishaq O, Mailhot Vega R, Zullig L, Wassung A, Walters D, Berland N, Du K, Ahn J, Leichman C, Jill Cohen D, Gu P, Chachoua A, Leichman L, Pearl K, Schiff P. Food as medicine: A randomized controlled trial (RCT) of home delivered, medically tailored meals (HDMTM) on quality of life (QoL) in metastatic lung and non-colorectal GI cancer patients. Journal Of Clinical Oncology 2016, 34: 155-155. DOI: 10.1200/jco.2016.34.26_suppl.155.Peer-Reviewed Original ResearchGI cancer patientsCancer patientsMetastatic lungHealthcare utilizationNutritional interventionFinancial toxicityFACT-G questionnaireTrial of homeAdvanced-stage cancerMetastatic cancer patientsLower healthcare costsQuality of lifeKnowledge of nutritionEligible patientsMalnutrition incidenceLonger hospitalMalnourished patientsPrimary endpointPS 0Oral alimentationPatient's symptomsQOL improvementShorter survivalFirst RCTGI cancers